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Abstract
Background: Studies have shown that steroids can improve kidney survival and decrease the risk of proteinuria in patients
with Immunoglobulin A nephropathy, but the overall benefit of steroids in the treatment of Immunoglobulin A
nephropathy remains controversial. The aim of this study was to evaluate the benefits and risks of steroids for renal survival
in adults with Immunoglobulin A nephropathy.
Methodology and Principal Findings: We searched the Cochrane Renal Group Specialized Register, Cochrane Controlled
Trial Registry, MEDLINE and EMBASE databases. All eligible studies were measuring at least one of the following outcomes:
end-stage renal failure, doubling of serum creatinine and urinary protein excretion. Fifteen relevant trials (n=1542) that met
our inclusion criteria were identified. In a pooled analysis, steroid therapy was associated with statistically significant
reduction of the risk in end-stage renal failure (RR: 0.46, 95% CI: 0.27 to 0.79), doubling of serum creatinine (RR=0.34,
95%CI=0.15 to 0.77) and reduced urinary protein excretion (MD=20.47g/day, 95%CI=20.64 to 20.31).
Conclusions/Significance: We identified that steroid therapy was associated with a decrease of proteinuria and with a
statistically significant reduction of the risk in end-stage renal failure. Moreover, subgroup analysis also suggested that long-
term steroid therapy had a higher efficiency than standard and short term therapy.
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Introduction
Immunoglobulin A (IgA) nephropathy or Berger’s disease is
the most common form of primary glomerulonephritis world-
wide [1–5]. It is one of the major factors leading to end stage
renal failure. About 15–20% of patients with apparent onset IgA
nephropathy will develop end stage renal failure within 10
years, and 30–40% within 20 years [6–8]. The disease is
characterized by accumulation of polymeric IgA1-containing
complexes in the mesangial areas [9,10]. IgA nephropathy can
occur at all ages, but most commonly in the second and third
decades of life, with a male gender preference [11]. Episodic
macroscopic hematuria has been reported as the most common
clinical manifestation (40–50% of cases) of IgA nephropathy
patients, especially in the second and third decades of life [12].
It has also been found that ,5% cases were complicated by
upper respiratory infection or acute kidney injury (AKI), the
most often in the elderly [13,14].
Only in recent years has the pathogenetic mechanism underlying
IgA nephropathy been found, which can be divided into three
essential steps: i) generation of abnormal IgA1 and formation of
IgA1 complexes; ii) generation of mesangial injury mediated by
interaction of IgA1 complexes with mesangial IgA receptors, and iii)
progression of IgA-mediated mesangial injury towards renal failure
[15,16]. Moreover, IgA nephropathy is highly variable both
clinically and pathologically [11,16]. The clinical features ranged
from asymptomatic hematuria to rapid progressive glomerulone-
phritis (RPGN) [14]. IgA nephropathy is most often associated with
microscopic hematuria or recurrent macroscopic hematuria, and
spontaneously resolving acute renal failure can also occur; this
condition can sometimes lead to chronic kidney disease as well
[13,17]. Pathologically, a spectrum of glomerular lesions can be
seen, and mesangial proliferation with prominent IgA deposition
can be observed in almost all biopsies [10,18].
The goal of treatment for IgA nephropathy is to prevent
sequelae. At the beginning of 1980s, corticosteroid treatment was
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syndrome, which was generally seen as predictive of progressive
renal insufficiency [16]. However, recent Cochrane systematic
review failed to show the benefit of such treatment for adults,
which only demonstrated the benefits and risks of steroids in renal
survival in children with IgA nephropathy [19]. Another
important review provided an unclear conclusion because it
included trials with low quality [20]. Several clinical trials have
been completed recently [21,22], which demonstrated both the
benefits and risks of steroids in renal survival in adults with IgA
nephropathy.
We performed a systematic review and meta-analysis including
the most updated evidence in the effects of steroid therapy on end-
stage renal failure, doubling of serum creatinine, urinary protein
excretion, and possible side-effects inpatients with IgA nephropathy.
Methods
Search Strategy
We systematically searched the English literature to identify all
relevant, randomized, double-blind, placebo-controlled trials
regardless of publication status (published, unpublished, in press,
and in progress), and to examine the effects of steroids on IgA
nephropathy. Relevant trials were identified with the following
procedure:
Electronic Searches: We searched the electronic databases
MEDLINE, EMBASE, Cochrane Renal Group Specialized
Register and Cochrane Controlled Trial Registry for relevant
trials to a time limit of Apr. 10, 2010 using ‘‘Steroids’’ and ‘‘IgA
nephropathy’’ as the search terms.
Other sources: We contacted authors to obtain any possible
additional published or unpublished data and we searched the
proceedings of the annual meeting in the Cochrane Renal
Group Specialized Register. In addition, we searched for
ongoing RCTs in the metaRegister of controlled trials using
the search terms ‘‘Steroids’’ and ‘‘IgA nephropathy’’ as the
above statement.
Study Selection
Two authors (Shi-Lei. Guo, Chun-Fang. Wu) screened the
primary searching results to identify any relevant trials that
required further retrieval (full text or abstract), and then they
independently reviewed these studies, looking for trials that met
the inclusion criteria (Figure 1). The inclusion criteria were broad
so that it would be possible to include all evidence now existing,
regardless of the study language, study quality, sample size and
other factors. The included studies were randomized controlled
trials or quasi-randomized controlled trials and any type of
treatment with steroids (methylprednisolone or prednisolone) was
compared to treatments without steroids.
Data extraction
Data extraction was performed by two reviewers (Shi-Lei. Guo,
Chun-Fang. Wu) independently using a standardized extraction
form. If there was any disagreement between the two reviewers, it
would be settled by discussion with a third reviewer (Yu-Hao.
Zhou) until a consensus was reached.
Data were extracted from the included trials in terms of
patients’ characteristic, doses and modalities of treatment,
methodological characteristics of the trials. The primary reported
outcomes were summarized in tables. One author (Yu-Hao Zhou)
entered the data into computer, and three other authors (Jia-Jie.
Zang, Chun-Fang. Wu, and Jin-Fang. Xu) checked it.
Assessment of Methodological Quality
The quality of the trials was assessed according to the pre-fixed,
including allocation concealment, blinding, Intention-to-treat
analysis, and completeness of follow-up. Judgments regarding
the presence of methodological biases were made according to
Cochrane criteria guidelines [23]. Any disagreement among the
three authors (Shi-Lei. Guo, Chun-Fang. Wu, and Jin-Fang. Xu)
was settled by discussion with a fourth author (Yu-Hao. Zhou)
until a consensus was reached.
Data Analysis
The effect of steroids on renal survival was evaluated in terms of
incidence of end stage renal failure, doubling of serum creatinine
and urinary protein excretion [24–26]. We used relative risk (RR)
with 95% confidence intervals (CIs) for binary data and mean
difference (MD) with 95% confidence intervals (CIs) for contin-
uous data. We also did subgroup analysis to assess potential effect
change for all results based on the type of control drug and
duration of treatment. All estimates of effect were derived using a
random-effects model with Mantel-Haenszel Statistics. Heteroge-
neity of treatment effects between studies was investigated visually
by scatter plot and statistically by the heterogeneityI2statistic.
When theI2statistic was 0% to 40%, it indicates that heterogeneity
is unimportant, 30% to 60% indicates moderate, 50% to 90%
indicates substantial and 75% to 100% indicates considerable
heterogeneity [27]. The P value is from the x2 test. All the
reported P values are two-sided and values of P,0.05 was
regarded as statistically significant for all included studies. All
analyses were calculated using STATA (version 10.0).
Results
We identified 1,378 articles from our initial electronic search, of
which 1,263 were excluded during an initial review (title and
abstract), we retrieved the full text for the remained 115 articles,
and 15 clinical trials met the inclusion criteria (Figure 1): they
contributed to the study of 1,542 patients with IgA nephropathy in
this systematic review and meta-analysis. Table 1 summarized the
characteristic of these studies and the important baseline
information of the included patients. The follow-up for patients
ranged from 3 to 281 months, and the number of patients included
in every study ranged from 20 to 702. Of these studies, two trials
[28,31] compared steroids with anti-platelet drugs. Five trials
[29,32,33,35,37] compared steroids with anti-inflammatory drugs
and/or anti-thromboyte. Six trials [21,22,30,34,39,40] compared
steroids with supportive treatment. Placebo was compared with
steroids in one trial [36] and only one trial [38] gave no treatment
for the control group. In addition, three trials [34,36,38]
investigated short-term steroid therapy, five trials [21,22,30,
32,40] investigated standard-term steroid therapy and remaining
seven trials [28,29,31,33,35,37,39] investigated long-term steroid
therapy. Some of the included studies keep low-quality because
many trials have design limitations. Table 2 shows the detailed
quality of included individual trials.
Effects of Interventions
Data for the effect of steroids on end stage renal failure were
available from fourteen trials. We also performed subgroup
analyses based on the type of control drug or the duration of
steroid therapy. In Figure 2, the pooled RR showed that the
application of steroid therapy had a statistically significant
relationship with reduced the risk of end stage renal failure (RR:
0.46, 95%CI: 0.27 to 0.79). Subgroup analysis based on the type
of control drug showed that compared with anti-platelet for the
Steroids in the Treatment of IgA Nephropathy
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associated with a statistically significant reduction of the risk in
end stage renal failure. Furthermore, the study of steroid therapy
vs no treatment or placebo also provided no evidence that
steroid therapy could reduced the risk of end-stage renal failure.
In contrast, steroid therapy reduced the risk of end-stage renal
failure compared with anti-inflammatory (RR=0.54, 95%CI:
0.33 to 0.88) or supportive treatment (RR=0.16, 95%CI: 0.07
to 0.41) with a statistical significance. Subgroup analysis based
on the duration of treatment indicated that standard term
therapy could lead to lower risk of end stage renal failure when
compared with control group (RR=0.28, 95%CI: 0.11 to 0.71),
while this could not be observed for short and long term steroid
therapy.
Data for the effect of steroids on doubling of serum creatinine
were available from nine trials. We also performed subgroup
analyses based on the type of control drug or the duration of
steroid therapy. As shown in Figure 3, steroid therapy was
associated with a statistically significant reduction of the risk in
doubling of serum creatinine (RR=0.34, 95% CI: 0.15 to 0.77).
Subgroup analysis based on the type of control drug suggested that
steroid therapy was not associated with lower risk of doubling of
serum creatinine when patients in control group received anti-
inflammatory treatment, placebo or no treatment. In contrast,
steroid therapy statistically reduced the risk of doubling of serum
creatinine compared with supportive treatment (RR=0.10,
95%CI=0.02 to 0.41). In addition, subgroup analysis based upon
the duration of treatment showed that compared with control
Figure 1. Flow diagram showing the number of citations identified, retrieved and included in final analysis.
doi:10.1371/journal.pone.0018788.g001
Steroids in the Treatment of IgA Nephropathy
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18788group, long term steroid therapy could lead to lower risk of
doubling of serum creatinine (RR=0.40, 95%CI=0.20 to 0.78),
while this could not be observed for short and standard term
steroid therapy.
Data for the effect of steroids on urinary protein excretion were
available from nine trials (Figure 4). Statistical analyses showed
that steroid therapy reduced urinary protein excretion compared
with control therapy (MD=20.47 g/day, 95%CI=20.64 to
Table 1. Characteristic of the included studies.
Source Population
No. of
Patients Interventions
Baseline renal function
and/or proteinuria
Follow up
(month)
Katafuchi R
2008 [28]
Been biopsied
with primary
IgA nephropathy
702 (1) Methylprednisolone 1 g/day|3 days plus Prednisolone
30 mg/day|2 years
(2) Prednisolone 60 mg/day|4 weeks and then tapered
off within 1 year, Prednisolone 20 mg or 30 mg/day|1 month
and Prednisolone was tapered and maintained for at least 2 years
(3) Anti-platelet agent or with no medication
Serum creatinine
(0.98+0.58 mg/dl)
62
Koike M
2008[29]
Light microscopic
findings
48 (1) Prednisolone was 0.4 mg/kgBW/day (20–30 mg/day) |4 weeks,
then reduced to 10–20 mg on alternate days|12 months and
5–10 mg on alternate days for a subsequent year
(2) dipyridamole or zilazep hydrochloride 150 or 300 mg/day
Steroid group serum
creatinine was 0.92+0.26 mg/dl
and non-steroid group was
1.15+0.35 mg/dl
24
Pozzi C
2004[30]
Biopsy-proven
Ig A nephropathy
86 (1) Methylprednisolone 1 g/day|3 days and again 2 and 4
months later, other day oral prednisolone 0.5 mg/kg|6 months
(2) Supportive treatment
Urinary protein excretion
levels of 1–3.5 g/d
120
Moriyama T
2004[31]
Been diagnosed
based on
light-microscopic
findings
60 (1) Prednisolone 0.8 mg/kg/day|4 weeks, then reduced to
20–30 mg on alternate days|12 months and 20 mg on
alternate days|12 months
(2) Anti-platelet agent
Steroid group serum creatinine was
1.21+0.44 mg/dl and non-steroid
group was 1.27+0.33 mg/dl
54.6
Katafuchi R
2003[32]
Biopsy-proven
new Ig A
nephropathy
103 (1) Prednisolone 20 mg/day|1 month, 15 mg/day|1 month,
10 mg/day|1 month, 7.5 mg/day|3 months
and 5 mg/day|18 months
(2) dipyridamole 150 or 300 mg/day
Steroid group serum creatinine
was 0.92+0.24 mg/dl and
non-steroid group was
0.91+0.21 mg/dl
64.5
Shoji T
2000[33]
Biopsy-proven
Ig A nephropathy
21 (1) Prednisolone 0.8 mg/kg/day, then reduced to
0.4 mg/kg/day |1 month and tapered to 10 mg|1 year
(2) dipyridamole 300 mg/day|1 year
Proteinuria,1.5 g/day of
protein and serum
creatinine,1.5 mg/dl
12
K.N.Lai
1986[34]
Presence of IgA
deposits in the
mesangium
34 (1) Prednisolone 40–60 mg/day|8 weeks, then
tapered by half|4 months
(2) no corticosteroid therapy
Steroid group urinary protein
was 6.5+2.8 gm/day and
non-steroid group was
4.7+1.4 gm/day
38
Kobayashi Y
1996[35]
Fulfilled the
three conditions
defining the
early stage of
progressive Ig A
nephropathy
90 (1) Prednisolone 40 mg/day|4 weeks, 30 mg/day|8 weeks,
25 mg/day|8 weeks, 20 mg/day|8 weeks, then
15 mg/day|6 months and thereafter was further tapered
(2) dipyridamole 300 mg/day
Creatinine clearance.70 ml/min 120
Welch TR
1992[36]
Been proved
Ig A nephropathy
20 (1) Prednisolone 2 mg/kg(,80 mg)|12 weeks
(2) placebo
Serum creatinine,140umol/l 3
Kobayashi Y
1988[37]
Ig A nephropathy
with primary
glomerular
deseases
96 (1) Prednisolone 40 mg/day|4 weeks, 30 mg/day|8 weeks,
25 mg/day|8 weeks, 20 mg/day|8 weeks, then 15 mg/day|6
months and thereafter further tapered on a gradual basis
(2) Non-steroidal anti-inflammatory and/or anti-thrombocyte drugs
Proteinuria.1.0 g/day 48
Julian BA
1993[38]
Biopsy-proven
Ig A nephropathy
35 (1) Alternate day prednisolone 60 mg|3 months
(2) No treatment
Creatinine clearance.25 ml/min 24
Uzu T
2003[39]
Biopsy-proven
Ig A nephropathy
45 (1) Methylprednisolone 1 g/day|3 day, then oral prednisolone
40 mg/day|4 weeks, 30 mg/day|4 weeks, 25 mg/day|4 weeks,
20 mg/day|4 weeks, 15 mg/day|2 months, and gradual
reduction in 6 months
(2) Supportive treatment
Serum creatinine,106umol/l 36
Manno
C[21]
Biopsy-proven
Ig A nephropathy
97 (1) Prednisolone 1.0 mg/kg/day|2 months,
then 0.2 mg/kg/day | 4 months
(2) ramipril
Serum creatinine was 1.08 mg/dl 96
Lv J[22] Biopsy-proven
Ig A nephropathy
63 (1) oral prednisone 0.8 to 1.0 mg/kg/day| 8 weeks,
then the dose was tapered by 5 to 10 mg every 2 weeks
(2) cilazapril
Serum creatinine was 1.1 mg/dl 48
Locatelli F
2001[40]
Biopsy-proven
Ig A nephropathy
86 (1) Methylprednisolone 1 g/day|3 day at the beginning of
vmonths 1, 3, and 5, and again two and four months later,
oral prednisolone 0.5 mg/kg|6 months
(2) Supportive treatment
Plasma creatinine
levels,1.5 ml/dL
64
doi:10.1371/journal.pone.0018788.t001
Steroids in the Treatment of IgA Nephropathy
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e1878820.31) Subgroup analysis based on the type of control drug
suggested that steroid therapy was not associated with reduced
urinary protein excretion when patients in control group received
anti-platelet treatment, placebo or no treatment. In contrast,
steroid therapy led to statistically significant reduced urinary
protein excretion compared with anti-inflammatory (MD=
20.41 g/day, 95%CI=20.61 to 20.21) and supportive treat-
ment (MD=20.62 g/day, 95%CI=20.92 to 20.33). Subgroup
analysis based on the duration of treatment indicated that there
was an association between significantly decreased urinary protein
excretion and steroid therapy in standard term (MD=20.52 g/
day, 95%CI=20.85 to 20.19) and in long term (MD=20.43 g/
day, 95%CI=20.64 to 20.23). But for short-term treatment,
there was no evidence showing that steroid therapy could reduce
the urinary protein excretion.
In addition, the analysis of adverse effecteventswas difficult,because
a majority of these studies reported few adverse effects. It is unclear
whether there were no events or they were not properly recorded, and
even worse some trials did not report adverse events intentionally.
Furthermore, it should be noticed that the reported adverse events of
treatment or control group are specific or nonspecific, such as stomach
bleeding and unusual-hypertension [40,41].
Discussion
An increasing number of trials have evaluated the role of
steroids in the treatment of IgA nephropathy and acquired various
results, for which medical practitioners have few evidence-based
treatment guidelines. In this large quantitative study, we
performed a comprehensive literature search with no restrictions
in publication status. More than 1542 patients were included to
examine the effect of steroids on end-stage renal failure, doubling
of serum creatinine and urinary protein excretion. The study
suggested that compared with non-steroid therapy, steroid therapy
was associated with clinically and statistically significant reduction
of the risk in end stage renal failure (RR: 0.46, 95%CI: 0.27 to
0.79), doubling serum creatinine, (RR=0.34, 95%CI=0.15 to
0.77) and also urinary protein excretion at the end of treatment
(MD=20.47 g/day, 5%CI=20.64 to 20.31).
Our results were consistent with the recommendations for the
management of IgA nephropathy which were published in 1999
[13]. The recommendation indicated that IgA nephropathy
patients should be treated with steroids to reduce proteinuria
and stabilize renal function. However, the recommendation
encountered criticism because it was based on a variety of sources,
including non-randomized controlled trials data and with
suboptimal methodological quality. Consequently, there was not
enough information to provide strong evidence.
This meta-analysis showed that for patients with Ig A
nephropathy, steroids could reduce the incidence of end stage
renal failure, doubling serum creatinine and urinary protein
excretion compared with patients receiving no steroidal treatment.
Subgroup analysis showed that steroids vs anti-inflammatory could
reduce the risk of end stage renal failure and the urinary protein
excretion with a statistical significance. However, there was no
evidence that steroid therapy protected against the doubling serum
creatinine risk compared with anti-inflammatory therapy. The
reason for this absence of difference could be that fewer events
occurred and that the incidence of doubling serum creatinine was
notreportedinKobayashi’study[37].Furthermore,steroid therapy
statistically reduced the risk of end-stage renal failure, doubling
serum creatinine and also urinary protein excretion compared with
supportive treatment. Subgroupanalysis based uponthe duration of
treatment showed that compared with control group, long term
steroid therapy was associated with a decrease of proteinuria and
with a statistically significant reduction of the risk in end-stage renal
failure, in addition, standard-term therapy was associated with a
statistically significant reduction of the risk in end stage renal failure
and urinary protein excretion. Finally, the P value for long-term
therapy was very close to 0.05 for reducing the risk of end stage
renal failure, which may be explained by the small amount of trials
including results in this aspect. These findings corresponded with
recent researches[40,42,43] that steroid therapy should be given for
a long-term therapy.
To minimize the consequences of heterogeneity among the
included studies, we performed a sequential exclusion of each trial
from the pooled analysis. These exclusions did not affect the results
of our meta-analysis.
Table 2. Risk of Bias in Studies.
Source Intention-to-treat analysis Allocation concealment Blinding Lost to follow up
Katafuchi R 2008 [28] No Unclear Unclear No lost to follow-up
Koike M 2008[29] Yes Unsealed envelops Yes: patients and caregivers No lost to follow-up
Pozzi C 2004[30] Yes Yes Unclear No lost to follow-up
Moriyama T 2004[31] Yes Unclear No No lost to follow-up
Katafuchi R 2003[32] No Yes No Lost to follow-up: 13 patients
Shoji T 2000[33] No Yes No Lost to follow-up:2 patients
K.N.Lai 1986[34] No Unclear No No lost to follow-up
Kobayashi Y 1996[35] No Inadequate No Lost to follow-up:44 patients
Welch TR 1992[36] Unclear Yes Yes: patients and investigators Lost to follow-up:3 patients
Kobayashi Y 1988[37] No Unclear Unclear No lost to follow-up
Julian BA 1993[38] No Yes Unclear Lost to follow-up:2 patients
Uzu T 2003[39] No No Unclear No lost to follow-up
Manno C[21] Yes Yes No Lost to follow-up: 6 patients
Lv J[22] Yes Yes No Lost to follow-up: 3 patients
Locatelli F 2001[40] Yes Unclear Unclear Lost to follow-up: 12 patients
doi:10.1371/journal.pone.0018788.t002
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doi:10.1371/journal.pone.0018788.g002
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18788Subgroup analysis is only done between-study hypothesis (not
within-study hypothesis) in our review, because individual patient
data and original data were not available. However, its validity
was acceptable according to recently proposed criteria [44,45], as
we only conducted 2 subgroup analyses, which were based on the
duration of treatment and on the type of control drug.
Recently, Cheng’s review [46] illustrated that glucocoticoids
significantly induced a protection of renal function and a reduction
Figure 3. Effect of steroids on doubling of serum creatinine in patients with Ig A nephropathy. CI, confidence intervals; RR, relative risk.
doi:10.1371/journal.pone.0018788.g003
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18788Figure 4. Effect of steroids on urinary protein excretion in patients with Ig A nephropathy. CI, confidence intervals; WMD, weighted mean
difference.
doi:10.1371/journal.pone.0018788.g004
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18788of proteinuria in patients with IgA nephropathy. This conclusion is
in accordance with our own results. In addition, our subgroup
analysis studied important factors which could affect the
interpretation of our data. The results of this meta-analysis are
promising because the outcomes consistently favor the use of
steroids interventions. In all the interventions tested in the
available trials, a long-term steroid therapy seems to be more
beneficial.
The limitation of this study includes the inherent assumptions
made for any meta-analysis, because the analysis uses pooled data
either from published papers or provided by individual study
authors, individual patient data and original data were not
available, which prevented us doing more detailed relevant
analysis and obtaining more comprehensive results. Furthermore,
different follow-up times and therapy dose also could have affected
our conclusions about the association between steroids and renal
function. We also did not have sufficient data to get detailed effects
of steroids on renal function. Therefore, we just gave a relative
result by comparing steroid therapy with non-steroid therapy and
provided a synthetic and comprehensive review.
For future research, promising interventions should be tested,
including dosage, duration of treatment or combination with other
influencing factors, such as cyclophosphamide, fish-oil, dipyri-
damole, antiplatelet drugs, etc, through which we might confirm
the optimal time of treatment, the optimal dosage and the optimal
therapy [47]. We suggest that ongoing trials would be improved by
the following ways: i). Adverse events of clinical trials should be
recorded and reported ii). Treatment duration and dosage should
be taken into consideration before evaluating clinical outcomes.
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